



## AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2005

AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2005				
(Rs. in thousands)				
Sr. No.	Particulars	Quarter ended	Quarter ended	Year ended
		30.06.2005	30.06.2004	31.03.2005
		Audited	Audited	Audited
1.	Net Sales	1,550,813	1,602,397	6,463,624
2.	Other Income	18,249	36,977	157,987
3.	Total Expenditure (a+b+c+d+e)	1,120,323	1,126,024	4,535,670
	a. (Increase)/decrease in stock in trade	(17,173)	28,076	(30,420)
	b. Consumption of Raw Materials and Traded goods	874,694	766,968	3,471,966
	c. Power cost	67,903	57,393	245,990
	d. Employee cost	103,010	111,686	420,435
	e. Other Expenses	91,889	161,901	427,699
4.	<b>Profit before Interest, Depreciation &amp; Taxes (1+2-3)</b>	<b>448,739</b>	<b>513,350</b>	<b>2,085,941</b>
5.	Interest and finance charges	2,602	6,501	19,931
6.	Depreciation	56,009	38,874	180,915
7.	<b>Profit Before Taxation (4-5-6)</b>	<b>390,128</b>	<b>467,975</b>	<b>1,885,095</b>
8.	Provision for current tax	68,049	23,420	98,298
9.	Provision for deferred tax	(6,816)	8,010	42,917
10.	<b>Net Profit (7-8-9)</b>	<b>328,895</b>	<b>436,545</b>	<b>1,743,880</b>
11.	Paid-up equity share capital	500,000	500,000	500,000
12.	Reserves excluding revaluation reserves	6,776,878	5,343,161	6,445,082
13.	Earnings per share (Par value of Rs. 5/-)			
	Basic - (in Rs.)	3.44	4.62	18.43
	Diluted - (in Rs.)	3.40	4.51	18.00
14.	Aggregate of Non-Promoter Shareholding			
	- Number of Shares	35,452,439	35,452,439	35,452,439
	- Percentage of shareholding	35.45%	35.45%	35.45%

SEGMENT REPORTING FOR THE QUARTER ENDED JUNE 30, 2005				
(Rs. in thousands)				
Sr. No.	Particulars	Quarter ended	Quarter ended	Year ended
		30.06.2005	30.06.2004	31.03.2005
		Audited	Audited	Audited
1.	Segment revenue			
	a. Enzymes	222,089	225,229	980,942
	b. Pharma	1,352,680	1,396,807	5,566,810
	Total	1,574,769	1,622,036	6,547,752
	Less: Inter-segment revenue	(23,956)	(19,639)	(84,128)
	<b>Net sales/income from operations</b>	<b>1,550,813</b>	<b>1,602,397</b>	<b>6,463,624</b>
2.	Segment results			
	Profit before interest, depreciation and tax from each segment			
	a. Enzymes	114,904	113,121	475,237
	b. Pharma	471,748	608,565	2,074,971
	c. Others			(36,354)
	<b>Total</b>	<b>586,652</b>	<b>721,686</b>	<b>2,513,854</b>
	Less: Interest	(2,602)	(6,501)	(19,931)
	Depreciation	(56,009)	(38,874)	(180,915)
	Unallocated corporate expenses net of unallocable income	(137,913)	(208,336)	(427,913)
	<b>Profit before tax</b>	<b>390,128</b>	<b>467,975</b>	<b>1,885,095</b>
3.	Capital employed			
	a. Enzymes	431,625	440,767	503,641
	b. Pharma	5,569,204	2,780,825	4,601,939
	c. Unallocable corporate assets	2,360,527	3,985,978	3,069,189
	Less: Corporate liabilities	(1,070,576)	(1,348,902)	(1,215,385)
	<b>Total capital employed</b>	<b>7,290,780</b>	<b>5,858,668</b>	<b>6,959,384</b>
	Less: Revaluation Reserve	(13,902)	(15,507)	(14,302)
	<b>Capital employed net of revaluation reserves</b>	<b>7,276,878</b>	<b>5,843,161</b>	<b>6,945,082</b>

**Note:**  
 The primary reporting of the Company has been performed on the basis of business segment. The Company is organised into two business segments, enzymes and active pharmaceutical ingredients (Pharma). Segments have been identified and reported based on the nature of the products, the risks and returns, the organisation structure and the internal financial reporting systems.

CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2005				
(Rs. in thousands)				
Sr. No.	Particulars	Quarter ended	Quarter ended	Year ended
		30.06.2005	30.06.2004	31.03.2005
		Audited	Audited	Audited
1.	Net Sales	1,739,572	1,741,973	7,125,664
2.	Other Income	17,778	36,658	156,247
3.	Total Expenditure (a+b+c+d+e)	1,234,624	1,205,988	4,887,081
	a. (Increase)/decrease in stock in trade	(17,173)	28,076	(30,420)
	b. Consumption of Raw Materials and Traded goods	912,224	796,272	3,607,601
	c. Power cost	74,606	59,099	255,726
	d. Employee cost	149,930	150,187	568,173
	e. Other Expenses	115,037	172,354	486,001
4.	<b>Profit before Interest, Depreciation &amp; Taxes (1+2-3)</b>	<b>522,726</b>	<b>572,643</b>	<b>2,394,830</b>
5.	Interest and finance charges	2,811	6,728	20,282
6.	Depreciation	71,130	45,949	223,445
7.	<b>Profit Before Taxation (4-5-6)</b>	<b>448,785</b>	<b>519,966</b>	<b>2,151,103</b>
8.	Provision for current tax	73,617	25,509	128,341
9.	Provision for deferred tax	(7,165)	8,010	57,726
10.	<b>Net Profit before minority interest (7-8-9)</b>	<b>382,433</b>	<b>486,447</b>	<b>1,965,036</b>
11.	Add/(Less): Minority interest	4,661	(4)	10,414
12.	<b>Net Profit (10-11)</b>	<b>387,094</b>	<b>486,443</b>	<b>1,975,450</b>
13.	Paid-up equity share capital	500,000	500,000	500,000
14.	Reserves excluding revaluation reserves	7,280,935	5,606,221	6,890,940
15.	Earnings per share (Par value of Rs. 5/-)			
	Basic (Rs.)	4.05	5.14	20.88
	Diluted (Rs.)	4.00	5.02	20.39

**Note:**  
 The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in India and comply with the Accounting Standard (AS 21) on Consolidated Financial Statements, issued by the Institute of Chartered Accountants of India to reflect the financial position and the results of operations of Biocon together with its subsidiary companies, Syngene, Clinigene and JV company, Biocon Biopharmaceuticals.

### Notes:

- The earnings considered in ascertaining the Company's earnings per share comprise of the net profit after tax. The number of shares used in computing the basic earnings per share is the weighted average number of shares outstanding during the period/year. The number of shares used in computing diluted earnings per share comprises the weighted average share considered for deriving basic earnings per share, and also the weighted average number of shares, if any which would have been issued on the conversion of all dilutive potential equity shares. In accordance with the revised SEBI (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999 (Revised), the ESOP Trust has been consolidated with the Company.
- Total number of shareholder complaints pending at the beginning of the quarter was 3. Complaints received during the quarter were 46. The complaints resolved during the quarter were 48. Complaints pending for redressal as at the end of the quarter were 1, which has now been resolved.
- The above results were reviewed by the Audit committee on July 19, 2005 and then approved by the Board of Directors at their meeting held on July 20, 2005.
- The figures have been reclassified wherever required, to conform with the classification in the financial statements for the quarter ended June 30, 2005.

For and on behalf of the Board

Sd/-  
**Kiran Mazumdar-Shaw**  
 Managing Director

Place: Bangalore Date: July 20, 2005